CorMedix (CRMD)
(Delayed Data from NSDQ)
$10.63 USD
+0.31 (3.00%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $10.71 +0.08 (0.75%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.63 USD
+0.31 (3.00%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $10.71 +0.08 (0.75%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Zacks News
Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 52.2% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 50% and 4.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Atossa Genetics Inc. (ATOS) and CorMedix (CRMD) have performed compared to their sector so far this year.
Here's Why CorMedix (CRMD) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CorMedix (CRMD) Is Up 10.44% in One Week: What You Should Know
by Zacks Equity Research
Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think CorMedix (CRMD) Could Surge 117.77%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 117.8% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 142.25%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to a 142.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CorMedix (CRMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 3.85% and 7.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Does CorMedix (CRMD) Have the Potential to Rally 135.51% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to a 135.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for CorMedix (CRMD) points to a 146.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
How Much Upside is Left in CorMedix (CRMD)? Wall Street Analysts Think 198.21%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 21.74% and 84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of -25% and 9.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.20% and 33.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 10% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Stock Jumps 14.8%: Will It Continue to Soar?
by Zacks Equity Research
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Puma Biotech (PBYI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 190.91% and 16.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -20.29% and 14.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?